The pioneering company in RNAi therapeutics, Alnylam Pharmaceuticals Inc. made an announcement today that the Ministry of Health, Labor and Welfare of Japan has given approval of ONPATTRO which would treat with polyneuropathy the hereditary transthyretin-mediated amyloidosis. ONPATTRO is the first ever RNAi therapeutic which got approval by the Japanese Authority and the Alnylam Pharmaceuticals Inc. will be launching and directly commercializing it in Japan.
The President of Japan Society of Amyloidosis, as well as, of International Society of Amyloidosis, Yukio Ando has passed the following statement: “hereditary transthyretin-mediated amyloidosis is disease which is genetic which can result in various symptoms of debilitation and frequently result in deaths. If you look back at its history in Japan, there were limited options for the treatment for people who are existing with this condition, where there is high prevalence of this condition of mutation of V30M. “He further said: “There has been paradigm shift in the way by which this disease is approached and treated by the approval of this treatment ‘ONPATTRO’ which has the potential to alleviate and possibly reverse the polyneuropathy’s symptoms and to enhance the quality of life
The Senior VP and Chief of Alnylam, Asia, Masako Nakamura passed the following statement: “We are very enthusiastic about ONPATTRO’s approval and feel proud to be the ones bringing this vital new treatment to the patients with hereditary transthyretin-mediated amyloidosis polyneuropathy in Japan. After its approval, we are looking forward to work with the hereditary transthyretin-mediated amyloidosis community to keep up with the raising of awareness regarding the disease, escalate the rate of diagnosis and then eventually deliver treatment to the patients who are suffering from this upsetting disease. I think we have achieved a significant milestone in our attempts for bringing RNAi therapeutics to people around the globe”